<SEC-DOCUMENT>0000914475-25-000006.txt : 20250127
<SEC-HEADER>0000914475-25-000006.hdr.sgml : 20250127
<ACCEPTANCE-DATETIME>20250127161201
ACCESSION NUMBER:		0000914475-25-000006
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250124
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250127
DATE AS OF CHANGE:		20250127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		25559154

	BUSINESS ADDRESS:	
		STREET 1:		6027 EDGEWOOD BEND COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-20250124.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7160e0d7-36dd-4ed3-83b4-20ba1c8aae2e,g:1ed33b26-508e-4e96-a509-f296f60944ec,d:721e5c1205744957bb33ee820937f828-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20250124</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000914475</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20250124.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-24</xbrli:startDate><xbrli:endDate>2025-01-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i721e5c1205744957bb33ee820937f828_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">January 24, 2025</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><img src="nbix-20250124_g1.jpg" alt="nbix.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:420px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-22705</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">33-0525145</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(State or Other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Commission</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">6027 Edgewood Bend Court</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">San Diego,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">92130</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">617-7600</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></td></tr><tr style="height:0pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">NBIX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i721e5c1205744957bb33ee820937f828_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.01.&#160;&#160;&#160;&#160;Entry into a Material Definitive Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2025, Neurocrine Biosciences, Inc. (&#8220;Neurocrine Biosciences&#8221; or the &#8220;Company&#8221;) entered into an Amended and Restated Exclusive License Agreement (the &#8220;Restated License Agreement&#8221;), which amends and restates in its entirety the Exclusive License Agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), dated as of June 12, 2020 (the &#8220;Original License Agreement&#8221;). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Restated License Agreement, among other things, the parties revised the Original License Agreement to reflect the conversion from sharing operating profits and losses with respect to the development and commercialization of osavampator (NBI-1065845 / TAK-653) to a royalty-bearing license, the return of rights to osavampator in Japan to Takeda, and the Company&#8217;s previous termination of DAAO inhibitors under the Original License Agreement, including luvadaxistat, and GPR139 agonists, including NBI-1065846. Under the Restated License Agreement, Neurocrine Biosciences will retain exclusive rights to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator, for all indications in all territories worldwide except Japan, where Takeda will reacquire exclusive development and commercialization rights. Osavampator is currently in development for treatment of patients with inadequate response to treatment of major depressive disorder.  Under the terms of the Restated License Agreement, each party is responsible for development costs for osavampator in its respective territory, and each party is eligible to receive royalty payments based on the other party&#8217;s net sales of osavampator in the other party&#8217;s territory. Takeda is now eligible to receive development and commercial milestones as contemplated in the Original License Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the terms of the Restated License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Restated License Agreement, a copy of which will be filed, with confidential terms redacted, with the Securities and Exchange Commission as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the period ending March 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.01.&#160;&#160;&#160;&#160;Regulation FD Disclosure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2025, the Company issued a press release announcing its entry into the Restated License Agreement with Takeda. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Restated License Agreement and upon the successful development and commercialization of osavampator, the Company expects tiered based royalties payable to Takeda to be in the mid-to-upper teens in the United States and low double-digits outside of the United States on a blended basis as percentage of net sales. Additionally, the Company would be entitled to receive royalties from Takeda on net sales in Japan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to historical facts, this Current Report on Form 8-K and certain of the materials furnished herewith contain forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to the benefits to be derived from transactions with Takeda Pharmaceutical Company Limited; statements regarding the clinical results from, and our future development plans with respect to, osavampator, as well as the therapeutic potential and clinical benefits or safety profile of osavampator. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements include: risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; our future financial and operating performance; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with U.S. federal or state legislative or regulatory and/or policy efforts which may result in, among other things, an adverse impact on our revenues or potential revenue; risks associated with potential generic entrants for our products; risks that the benefits of the agreements with Takeda may never be realized; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024. Neurocrine Biosciences disclaims any obligation to update these forward-looking statements after the date hereof other than required by law.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix2025127-exhibit991.htm">Press Release issued by Neurocrine Biosciences, Inc. on January 27, 2025</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i721e5c1205744957bb33ee820937f828_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: January 27, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Legal Officer</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nbix2025127-exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5f31f0c507af48a5aa883c7bda9bd6a6_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:36pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845&#47;TAK-653) </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">-&#160;&#160;&#160;&#160;Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">-&#160;&#160;&#160;&#160;Takeda Reacquires Rights to Osavampator in Japan</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">SAN DIEGO, Jan. 27, 2025 &#8211; Neurocrine Biosciences (Nasdaq&#58; NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845&#47;TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8220;This streamlined collaboration structure allows Neurocrine to focus on bringing this important medicine to patients as quickly as possible,&#8221; said Kyle Gano, Ph.D., Chief Executive Officer at Neurocrine Biosciences. &#8220;With the recent successful completion of our End-of-Phase 2 meeting with FDA for osavampator, we look forward to beginning the Phase 3 program in the first half of this year.&#8221;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8220;With its long-standing expertise developing therapies for serious psychiatric disorders, Neurocrine is the ideal partner to develop osavampator,&#8221; said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda. &#8220;As it continues to progress through clinical development, osavampator has the potential to add a meaningful new treatment option for patients with MDD.&#8221;  </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">About the Collaboration with Takeda</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">In 2020, Neurocrine Biosciences and Takeda entered into a strategic collaboration to develop and commercialize compounds in depression and schizophrenia, including an exclusive license to both osavampator and NBI-1070770, which are being studied for the treatment of major depressive disorder, as well as a preclinical GPR139 antagonist development program. </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">About Osavampator</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Osavampator is a potential first-in-class, investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development for patients with MDD who have not benefited from treatment with at least one antidepressant in their current episode of depression. In April 2024, Neurocrine announced positive topline data for its Phase 2 SAVITRI&#8482; study in adult subjects with MDD. Neurocrine plans to initiate a Phase 3 program in the first half of this year.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">About Major Depressive Disorder</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Major depressive disorder (MDD) is a serious disorder characterized by a persistently depressed mood, loss of interest, poor concentration, and decreased energy, among other symptoms. According to the World Health Organization, MDD is one of the leading causes of disability, is a serious condition that presents an increased risk of suicide and self-harm, and is associated with increased all-cause mortality rates. More than 21 million people in the U.S. live with MDD and it is estimated that roughly a third of those do not respond to available antidepressants.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">About Neurocrine Biosciences</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose&#58; to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (formerly Twitter) and Facebook. (*in collaboration with AbbVie)</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. SAVITRI is a trademark of Neurocrine Biosciences, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">  </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Forward-Looking Statements</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to the benefits to be derived from transactions with Takeda Pharmaceutical Company Limited&#59; statements regarding the clinical results from, and our future development plans with respect to, osavampator, as well as the therapeutic potential and clinical benefits or safety profile of osavampator. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements include&#58; risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials&#59; our future financial and operating performance&#59; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties&#59; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates&#59; risks that the potential benefits of the agreements with our collaboration partners may never be realized&#59; risks that our products, and&#47;or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse&#59; risks associated with U.S. federal or state legislative or regulatory and&#47;or policy efforts which may result in, among other things, an adverse impact on our revenues or potential revenue&#59; risks associated with potential generic entrants for our products&#59; risks that the benefits of the agreements with Takeda may never be realized&#59; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Neurocrine Biosciences, Inc.&#58; Media&#58; Tony Jewell, 1-609-576-3800, media&#64;neurocrine.com&#59; Investors&#58; Todd Tushla, 1-858-617-7143, ir&#64;neurocrine.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nbix-20250124.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7160e0d7-36dd-4ed3-83b4-20ba1c8aae2e,g:1ed33b26-508e-4e96-a509-f296f60944ec-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20250124" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20250124">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20250124_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20250124_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.neurocrine.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nbix-20250124_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7160e0d7-36dd-4ed3-83b4-20ba1c8aae2e,g:1ed33b26-508e-4e96-a509-f296f60944ec-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3f0c7494-95f3-43cf-b0f3-98514a43ce69_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d47ce261-e1e2-4c15-8064-e9d4214a1f8d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7cb778ce-6d1e-4bfa-9358-2a40e135d1a5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4953b68d-b162-431e-9666-9d4c789cd201_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4eba57cd-594c-4d19-b702-adaeeaebaf1d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_297a5330-4545-4b64-8364-6462def4cc21_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c00618f3-b4f4-49bd-9ef3-67b638389b24_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ef980fd2-10b0-4550-80d3-161dc5b4db1f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_67636ffd-b70e-417e-8849-e54cf6b9fb49_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5008fe03-3041-465e-8ebf-331a410966d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_914780de-0c0f-4c83-b8bd-166eea232c23_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_eda001ab-578d-4cfd-978f-2f04378a5508_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8d359b2e-a867-46fb-8ddc-2f50caefb8f8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c7a4da10-1487-4320-9806-9222154a6da8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_17eca0c2-014f-4344-a8f3-8570ce0b91ac_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f485c1ad-e371-4dc8-aea0-342bf362d305_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3ae6b3e3-ed6f-450d-bc29-553b57a0f1a6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a56b2c77-bc92-40a6-82f8-244bce165a3f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b086a6a7-5e97-4a3a-9ca0-e1d2c6f85b35_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_92a0c137-04db-4a22-a95c-cac1d3eca0b0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_da3e6239-1462-4537-a52a-43ce5c1b8f0b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_bcd83839-2ebd-47fa-b9ed-f44bf6163c89_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nbix-20250124_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7160e0d7-36dd-4ed3-83b4-20ba1c8aae2e,g:1ed33b26-508e-4e96-a509-f296f60944ec-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20250124.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6846a214-306d-4d25-9151-d37499d7ccee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_DocumentType_6846a214-306d-4d25-9151-d37499d7ccee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_affafc76-98b0-419a-a97d-750f90e5ed96" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_DocumentPeriodEndDate_affafc76-98b0-419a-a97d-750f90e5ed96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2f30a30e-ba1d-4d57-9cdc-2c474e113d1e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_EntityRegistrantName_2f30a30e-ba1d-4d57-9cdc-2c474e113d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f308d613-2d45-4af7-90ec-acb8d6fae706" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f308d613-2d45-4af7-90ec-acb8d6fae706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c05b7756-f0b8-474b-8a46-35f57a55450b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_EntityFileNumber_c05b7756-f0b8-474b-8a46-35f57a55450b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_587ff67d-558e-46c5-b5f9-9dad83f0a9a2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_EntityTaxIdentificationNumber_587ff67d-558e-46c5-b5f9-9dad83f0a9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_523bd46b-4af1-4644-b1be-697886ec601d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_EntityAddressAddressLine1_523bd46b-4af1-4644-b1be-697886ec601d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d0041a7a-2a07-4da6-b87e-6074f437ea79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_EntityAddressCityOrTown_d0041a7a-2a07-4da6-b87e-6074f437ea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_316b9f86-6dc1-42c2-acb2-e755d48e3522" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_EntityAddressStateOrProvince_316b9f86-6dc1-42c2-acb2-e755d48e3522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_97345097-c3d1-4018-968b-4a3d17223c96" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_EntityAddressPostalZipCode_97345097-c3d1-4018-968b-4a3d17223c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_62476fa6-77f5-48ab-9c68-c3e887d23ac4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_CityAreaCode_62476fa6-77f5-48ab-9c68-c3e887d23ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fa531118-bd3d-4fa4-a225-b517bb0d9aee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_LocalPhoneNumber_fa531118-bd3d-4fa4-a225-b517bb0d9aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6620f317-2f45-41ee-965e-c04e6f9abafa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_Security12bTitle_6620f317-2f45-41ee-965e-c04e6f9abafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e332f2c7-c5d2-4df7-88e7-f330e6c1b4a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_TradingSymbol_e332f2c7-c5d2-4df7-88e7-f330e6c1b4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8e08336b-5e0f-469d-9628-8d6e6a847267" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_SecurityExchangeName_8e08336b-5e0f-469d-9628-8d6e6a847267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_0e72df2a-794b-4492-9653-2c9e5d7bccb2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_WrittenCommunications_0e72df2a-794b-4492-9653-2c9e5d7bccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0c8d421d-c07f-4453-94a5-729f23238bdd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_SolicitingMaterial_0c8d421d-c07f-4453-94a5-729f23238bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1dc300d9-26ae-4b1d-bcce-4fa9cc4b3bad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_PreCommencementTenderOffer_1dc300d9-26ae-4b1d-bcce-4fa9cc4b3bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_afc1e4e3-da62-4293-a770-442d3c23d209" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_afc1e4e3-da62-4293-a770-442d3c23d209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a62edaa3-fc8d-483e-a58b-fa888d6e0873" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_EntityEmergingGrowthCompany_a62edaa3-fc8d-483e-a58b-fa888d6e0873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2e783996-c9ef-4414-8f7b-40bec82777fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_AmendmentFlag_2e783996-c9ef-4414-8f7b-40bec82777fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5ead6a93-4b2d-4751-9ac0-d9171f0f34d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc2d3d8-f3f7-4dfe-b257-457a9379f8bc" xlink:to="loc_dei_EntityCentralIndexKey_5ead6a93-4b2d-4751-9ac0-d9171f0f34d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>nbix-20250124_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20250124_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MR:G++?KO,[ZZ=-["QGBEC:/'2X35&/LW**Y[OF]ZFI[;;NWH?=GBS]I;X>^
M_$-QI.M>-?#.E:I:;?/M;K48HIHMRAAN4G(RI!^AK/\ ^&Q/A3_T47P;_P"#
M:'_XJOS3_P""EB@_MM>-N/XK3_TDAK#^"_[#_P 2/V@O!G_"0>%=%L[[2OM#
MVWFR:A# WF)C<-KL#QD<UZ%/AW"_5X5ZU5Q4DGK9*[5[:GQN.\;^(?[;Q.3Y
M9E\:TJ4YQ2BIRDXPDXW:C\K]-3]2H?VO_A7<31QQ_$/P<\DC!$4:K"2S$X '
MS=2:[#Q=XXTKP)8QW&K7B6L=Q((85VM))/(03L1%!9VP"<*"< GH#7Y>^'_^
M"77QHL/$.GW$OAG3EBM[N*5R-7MCA5=2?XO05]]?M3?##4O'EM:36<-U<VIM
M9-/NOLL:37%FKW%M,9HXG(63*V[1LO)(D'#*&!\K&Y?@Z56$*57F3O=W6GW=
MS]"X5XTXFS# 8O$9EESHU*?)R1<9KGO?F^*U^6RO;17U:1Z3X4\;:5XWTUKO
M2[R.ZACD,,@P4DAD&,HZ, R, 0=K '!!Z$45\R-^QMXJ^(>C:3)#JUQX7CTN
MR33]MQE9M2V%F^U.B$B+=OV",D[$C0#"@*"N9X/#7_C6^3?Y'M4^*<_<4UED
MI:+53C%/T4M5\_78Q?\ @I!\=3XO^/?PE_9YTR=E_P"%A:Q;7GBDQM\PTF*4
MN;8^@G\F0,.Z1D='KYL_X*G^/YO&?[8.L6)D+6GAFTMM-MT[)F,3/@>[2D?\
M!%<9X3^.7_"RO^"[5GXBNIA+:KXRFT&S)^ZL4,,ME"!]6&[ZN?6MC_@H_H,O
MA_\ ;4\<+(#B\FM[R,_WE>VB_J"/PKZ#AVC&&*47OR-_-M7_  T,?I?8"ME7
M">68*GI&<HRGYRDJC:?IRQ7_ &ZCP^NJ^"OP<UKX^_$O3/"OA^%9-0U)SEWS
MY5K$O+S2$=$4<GN3@#D@5RM?;/\ P3?\ Z]X=_9=^)GCCPAI9U3QOJDG]@Z*
MJLBM#M5"S[G(4 /*'.3@^2*^IS+%/#T'-6OHE?:[TU\ENS^&^!^'8YUF\,)5
MYO9Q4ISY5>3A!.344M7*5E&-NK1+XK^-'PW_ .":L$WA7X>:/9^,?B3&GEZO
MKU\,I:28Y0E>1C_GC&0%XW,6!KY[^(7[=GQ<^)5W))?>.=9LXI/^7?3)/L$*
MCT BP3_P(D^]>B:3_P $D_C)KRM<7H\-V,\S&23[9JK22NQ.26,:."2223GK
M6'\0/^"6OQF\$6,EU#H>FZ_#$-S#2K]9)<>T<@1F^B@FO*PTLL@[SJ1G-[R;
M3N_*^B\DC](S; \>8Z/L</A*N%PD?AI4XRC&,?[R5I3EUE*=VW=Z;'D]E^T3
MX^T>Z$]KXZ\803*<AUUFXSG\7KV#X.?\%5_B-\/G%CXJ:S^('A^8>7<VNI1H
MERT9^\%F5<-D=I%8'VKYMUW3[SP_JMQ8ZA:W5A?6CF.>VN8FBFA8=F5@"#]:
MS99Z]#$87#UHVG!->GY,]S@O+\XP=13H5ZD7U7,VGZQ=T_1IGV]-^SWX3^,5
M[9_'/]EBX30/B!X1G%]J7@V0B".ZR#YD CSB(RKO7Y289 >-K#-?H!\'_B?8
M_&?X8:'XITU)H;76K1+@0S*5EM7Z20R X(DC<,C ]&0BOQ#^"_QQ\0?L]?$O
M3O%?AJZ-OJ6GM\T98^3>Q$C?!*/XD8?D<$8(!K]J/V<OB1X?^,GP@TGQ=X9@
M6UT_Q,K:A)"/O0W#$B=6'3>) P;'5@3WR?B,\P<J-G>\>C>Z\GW\GZG]+<)X
M#V/-6A%4^?6<4K1<NDXK[+:TDEH[)JUG?N*^??\ @JW_ ,HXOC)_V+-S_(5]
M!5\^_P#!5O\ Y1Q?&3_L6;G^0KP([H^JQW^[5/\ "_R9_//\./!5U\2_B%H/
MANQDACOO$.HV^F6SS-MC66>58T+'LNYAD]A7<?"#XH>-/V$_VG[37+.WFTOQ
M=X#U22TOM/G)59MC&.XM)<=4D4%<CU5AT!K-_9._Y.J^&/\ V-VD_P#I;#7Z
M5?\ !P!_P3]_M33A\=_"=C_I5C'':>+[>%>9H!A8K['K'Q'(?[FQND9-=G,N
M:SZGY/A\OJ5,-/%T'[U-I_+>Z\UOZ'HW_!6+X_>'_P!J'_@CQ_PG7A>X^T:1
MX@O]*G16_P!9;2"[19(9!VDC<,C#U4]L&OSJ_P""37_*1[X2_P#86E_])+BO
M.O!7[3&N>%?V8_&OPIDW7GAGQ;?66JPQM(?^)9>6\J,TB#IB6-0C#U1#V.?1
M?^"37_*1[X2_]A:7_P!)+BJC#E@T3BLR^O9EAJ[W]Q/U4OUW/K[_ (.4?^1J
M^#__ %[:M_Z%:5\X_P#!*/\ ;L\,_L%_$_Q9KGBC2=>U:V\0:5#80)I<<3R1
MNDI<EO,=!C![$G-?1W_!RC_R-7P?_P"O;5O_ $*TKY@_X)B_L$:;^W_\1_%&
M@ZEXDU+PS'X=TV&_CFL[:.=IR\I0J0_  QGBKI\OL?>V_P""&</%+B23P7\2
MZM>W\B[Z;'WRO_!Q3\)6(_XHWXC<D#_CVL__ )(K[5^,=RM[\"_%4R@A9M!N
MW /4 V[FO@-?^#;SPJI7_BZWBGY2#_R"[;_&OT!^*.D23?!GQ%I\&Z21M%N;
M>/CESY#*/SKDJ^RNO9GW>3RSB5.M_:J2T7+:W9WV;\C^:*R_Y!,/_7)?Y"OZ
M=/"/_(J:7_UZ1?\ H K^8NV_=:0F0<I",CZ"OZ:?AKK5MXD^'/A_4;.5;BSU
M#3;>Y@E4Y62-XE96'L00:[<RVC\_T/B/"UKGQ*\H?^W'P5_P<1_\D1^&_P#V
M,4W_ *225\Z?\$'?^3ZI/^Q7OO\ T;;5] _\'$VMVL?PN^&.FF5?ML^M75TD
M6?F,:6^QFQZ!I$'XUX+_ ,$%-/EN_P!M^^FC4M':>%;QI3C[H:>V4?F:UH_[
MD_F>?G&O&U-+^:'_ *2CDO\ @LE_RD7\<?\ 7MIG_I##7U9_P1F_:J^&WP5_
M9'O-'\7>./#/AW59/$=Y<K::A?I!,8FCA"OM8YVDJ<'V-?*?_!9+_E(OXX_Z
M]M,_](8:\XT;]D;Q1KW[)>H?&2R:QNO#.DZN=)OK9-_VRUQL'GL-NWRMTB*2
M&R-V<8!-=GLH5,-"$W;;\CY?^U<7EO$F,QF#I^TE&56Z=](\VKT['US_ ,%I
M/VS_ (=_M ^$_"/A7P5K%CXHO-*U)]2N[^SR]O:IY31B)9,89G+Y(4D (,\D
M5Q'_  0Y^'^H>)_VT)-<MXW_ +.\+Z)<O>2X.T-/MBBCSZM\[ >D9KY=^!'@
MO0_B/\8_#GA_Q+KLGAG1=:O4L[C5$@6;['O^5&*L0 I<JI8G"AMQ! Q7[P?L
MN_LI^#_V0_ANOAKP?920PR2>?>WEPWF7>HS8QYDKX&3@8  "J. !6>*G#"X?
MV$;W?],]3A7!XSB;/O[=Q'+&-*46TM[Q7NI*[=M+MO1ZI>7X;_M&_$^Z^,O[
M0'C3Q5>R-)-K.LW,RY.=D2N4B0>RQJBCZ5^O'_!*#]G?2_@A^R%X;U.*TB77
M_&EK'K6IW94>9*)1NACW==B1E0%Z9+'JQK\>?C7X!NOA?\9_%WAJ]C,=SHFL
MW=FX/<+*VUOHRE6'L17[._\ !,'XTZ?\9_V+O!;6MQ')J'ANQCT/4H ?GMIK
M=1&-P_VD"./4.*TS:ZPT5#X;K\M#D\*53GQ#B)XO^-RR:OO?F7/;S_&U_,^@
M:_(/_@L7^SYI7P2_:@M=4T.UCL=.\;V+:C+;1*%CBNTDV3%0.@?,;D#^)F/>
MOU\K\F?^"VGQBTWXA_M/:3X?TVXCNO\ A"],:VO70AE2ZF<2-%D=U18\^A8C
MJ#7#D;E]9LMK._\ 7J?;^,T,,^'G*M;G4X\G>]];?]NWOZ'<?\$9_CS<^!?A
M-\8M+E9IK7PUI_\ PE%K$Q^5&$,JR@?[WDQ'\Z^#[S5+SQ%?3WUS(UUJ&I2O
M<3.YRTTTC%F)/J68_G7VY_P1W^#%[X]^&?QPO(T98]:T0>&[9B/EDFDAF9@#
M_L^9%_WU7P_"D^FLJLACNK4X*-P4D0\@_1ABOIL&H?6:W+O[OY'\^\45,4^'
M<J5>_):MR_\ @S]%:WD?NW^R?^S]I/[-'P*T'POI=M'%-;VR2ZA.%'F7MVR@
MRRN>I);(&>BA0. *[7QAX0TSX@>%M0T36K*WU'2M4@:VNK:9=R31L,$$?UZ@
M\CFL/X"_%O3?CI\'?#OBS29XY[36K*.<[3DQ28Q)&WHR.&4CL5-=1J&H0:38
M3W5U-';VMK&TLTLC!4B11EF8G@  $DFOAZDJGM&Y?%?YW/['R^C@UE].EADO
M8\B26G*XVT\K-'R0/^"*/P@48_M#QQCT_M.+_P",UT?[<WPZM/A%_P $S?$W
MABPNM0O+'0M-L[.VEO91+<-&EW %#,  <+@#@< 5MC_@J-\!VZ>/[4^XTZ\Y
M_P#(59G[?7C_ $GXI_\ !.#Q=XBT*Z-]H^K6-K<6EQY3Q>=&;R##;7 8 XXR
M!Q7JTZF,E7I?6>:W,K73[GYMC,'PK1R;,7D'L?:/#U>;V<HM\O(]TF]+V/S/
M_91\0V/A/]IOX?ZIJ=U!8:;I^NVMQ<W,[A(X(U<%F9CP /6OUB\0_M]_!OPW
MH\]Y)\0O#=TL*%O*L[H7,TF.RHF6)/3I7X^_"SP!=?%?XD:#X7L9K>WO?$%]
M%802SY\J-Y&P"VT$X'L":T?C)\(=8^ WQ0U;PEKT<::GH\PC=X\F*=" R2H2
M 2C*01D ]C@@U]9C\KH8RM%5)--+9=KG\V\$^(6;\+Y76G@L/&=*<TG.5[*?
M+I'1KHK^>I4^('B6'Q=X^U[6K>W^QVVK:C<WT4&/]2DDK.J<<<!@.*_67X.>
M![[X<?\ !.NST?4HVAO[7P?<-/$XPT32022;".Q7?@CU%?,G_!*W]D3X?_%O
M25\<ZM?3:YKGA^^\M]$FC5+6PE!W12N,DS!EPRDX4$,-I*YK[J^-_P#R1;Q?
M_P!@2]_]$/7CY]F$)U882"^%J]^^R_X<_5/!O@O$X3 8KB3&25\13DH*+3]U
M^])NVB;:2Y=XV:=GHOP_TS[UK_O1_P Q7Z6?\%CO^36=!_[&*V_])[BOS3TS
M[UK_ +T?\Q7Z6?\ !8[_ )-9T'_L8K;_ -)[BO;S;_?L+ZO]#\H\-_\ DD.(
M?^O=+\ZA^>/PZ^&^K?%37+G3=%@^U:A;V%QJ @'WYT@3S'5!W?:"0.Y&.I%>
MD?L+_M53?LL_&:WU&>21O"^M;+36H5R?W6?DG _O1$D^I4N.]='_ ,$J_P#D
M]?P__P!>%]_Z(-:O_!3C]D;_ (4)\4O^$HT6U\OPGXLF:0)&N$T^\.6DA] K
M\N@_WU'"BNK$XJE4Q+R^NM)1NOQNO72Z/ R/(<PP614^-<ID^?#UG&2[)*#C
M*W6+<G&:ZIKI<]4_X+4ZA!JVB_"^ZM9H[BVN3?RQ2QL&25&2V*L"."""""*Y
M'_@BY_R7WQ9_V+X_]*8Z^</&?QQU3Q]\'/"/A#4LW$7@N>Z.GW+-EA;S"/$)
M]D9#M/96 _A%?1__  1<_P"2^^+/^Q?'_I3'7!B,++#9/.A+I?[N;3\#Z[)>
M)*.?>)N%S:@N55'!M/I)45&2\[232?5:GE__  4L_P"3VO&W^]:?^DD->H?L
M-?\ !17PE^R[\#1X7UK1O$=]>_VC<7GFV,<+1;9-N!EY%.1CGBO+_P#@I9_R
M>UXV_P!ZT_\ 22&N]_8P_P"";VD_M4_!@>*KSQ5JFCS?;Y[/[/;VL<B8CVX;
M+'.3FM:WU5Y92^N7Y;1VOO;R.'*Y<0QX]S!\,J+Q'M*_Q<MN7VFOQ-+MYGU#
M\#_^"HG@KX\?%71_".EZ%XIM+_6G>.&:ZB@6%"D;R'<5E)Z(1P#SBOI:OE/]
MG_\ X)6Z-\ OC%H?C"V\8:OJ4^B222);36<2)+OB>/DJ<C ?/X5]65\/F:P:
MJ+ZE?EMK>^^O?Y'];< SXFE@9OBF,56YWR\O+;DY8V^%M7YN;S"BBBO-/NC^
M;/0O'FI>'/B5;^++*1EUBQU9=9A<GGSUG\X9/^\.:_2;_@I7H]C\=/AO\._C
MMX97SM%\3:9%9WS)R;=CEXM_^TK&:)O1D45^=/Q;\%R?#WXQ>+O#\J>7)H>N
M7M@5(Z>5<.@_0"OJS_@F9^V+X?\ "6A:Q\%?BA(LGPU\:LRVUU,^U=%NI",Y
M;^"-V"L'Z1R -P&8C[2$Y4IPQ--7Y=UWB]_\T?M'TA?"O_7G@^=#!K]]!<T/
MP:V]%MKRN5KMH\GK](/^",'CBWU/X'>)O#VY?MFCZR;LKGDQ3Q)M/_?44@_"
MOC7]JW]D?Q%^RKXP:WOXY-0\.WCDZ7K429@O$/*JY'"2@=5/7JN1S4W[%'[3
M,G[+'QSL]=F\V30KY/L.LPH-S-;L0?,4=VC8!@.I 8?Q5[V:48X_ OV#OU7R
MZ?IZG^1_A_F5;@_B^G_:\'3Y6Z=1/[*DK<WFD[2NKIQ5U>Y^QE&:IZ!K]EXI
MT2TU+3;J&^T^_A6>WN(6W1S1L,JRD=00:^;?^"I_[8=O^S'^S[>:5IMXJ^-/
M&4,EAI<2-^\M8F&V:Z([!%)"GN[+Z''YG1HSJ5%2CNS_ $8R/+:V:XNE@\'[
MTJC236JL_M>B6K?8\;^(7B#P'_P5=TWX@:7X?T^'2?BA\/+FY.B708?\5!81
MR,B$M@;HW(VE3DQLR,#AB#^><\C1NRNK1R(2KHPPR,#@@CU!X_"O2_\ @F1X
MSN/ '[='PZDM'9$U"]?2IU!XDBGB="I]?FV-]5!H_;N\*P^!/VQOB1IMLBQ6
MZZU)<QHHPJ"=5G('MF0U]S@6Z%1X9/W;)KRZ-?J?2^)'AG@<MSZ"P,?=J04O
M.Z?*_757^=NAY7+-7Z5?\$*_B)<:Q\*O''A>:3=#H>J0WULI/W%N8V# >V^$
MGZL:_,N2:OT1_P""".BR-:?$[5"#Y+2Z?9J<<%E6=V_(.OYUGGEGA)7\OS1A
M6X=6%RR==K:WXM+]3]$*^??^"K?_ "CB^,G_ &+-S_(5]!5S?QA^$NA_'CX7
MZYX-\36LE[H'B*T>ROX$F>%I8FZ@.A#+]00:^%CH[GQ>*INI1G3CNTU]Z/YK
M_P!D[_DZKX8_]C=I/_I;#7]-6NZ'9^)]$O--U&UAO=/U"![:YMYD#QSQ.I5T
M93P59200>H-?+/@W_@B7^SKX!\7Z3KNE^#]2@U+0[V'4+.1M>O7$<T4BR(Q5
MI2#AE!P00:^L*TJ34MCP^'\IK8*$XU[/F:VU_-(_G?\ ^"EO[#=Y^PC^TC>Z
M##'<2>#M<WZCX9NW^;?;%OFMV;O) Q"'N5,;?Q5/_P $FO\ E(]\)?\ L+2_
M^DEQ7[G_ +3_ .R)\/\ ]L;P99Z#\0="76K'3KL7MJ4GDMYK:4*5)22-E< J
MQ!&<$8R#@8\S^#?_  2+^!/P#^*&B^,O#'A?4+'Q!X?F:XLIWUJ[F6)RC(24
M>0JWRNPP0>M;+$+DL]SYZMP?6AF$:^'<?9J2E9MW233:V^[4^.O^#E'_ )&K
MX/\ _7MJW_H5I7QS^PO^W=XD_8)\::[KGAG1=#UJY\06,=A-'J9E"1(DA<%?
M+8'))QS7[@?M3?L'_#/]LV\T2X^(.BW6K2>'4F2Q,.HSVOE"4H7SY3KNSY:]
M<XQ7E _X(<?LWC_F3=3_ /!_??\ QVJIXB"AR21&;\+YE6S.6/P<XQVLVW=>
MZE_*UW/C%?\ @XM^*K?\R'\/O^^[S_XY7Z:?L4_'74OVG/V5?!?CS6+*QT_4
MO$UA]JN+:SW&")O,=<+N);&%'4UXV/\ @A[^SB/^9.U/_P ']]_\=KZ0^#7P
M@T'X!_##1O!_A>UDL= T&#[-90/,\S1IN+8+N2S<L>236=:=)QM35F>UD&!S
MJA7E+,JRG"VB3ZW6OPKI?J?AC_P4I_8FUC]C+]H?58OL,W_"$^)+R6]\.Z@%
M)A,;L7-JS=!+$25VGEE"L."<._9W_P""I'QI_9E\!0>%_#?B2SN-!LP5L[35
M;!;P6*GG;$Y(=4!Z*25'8 5^[/C_ .'>@_%7PK=:'XFT?3=>T>]7;/9W]NL\
M,GU5@1D=CU!Y%?+OBK_@AW^SWXEU1KJ'P]KFBJYR8-/UJX2$?179L#V&*ZZ>
M-IN/+65SY',. \PH8N6)R6MR*5]+N+5^ETG==KVZ;[GY ?'C]HKQE^TYX\/B
M3QSKEQKNK,@MH2R+'%;1YR(H8D 5%W$G"C))R<FOU6_X(H?L0:O^SI\,M6\<
M>+;&73?$WC9(H[:QG3;-I]@F602#JLDK-O*GE0L8.#D#V[X!?\$T_@K^S9K-
MOJGAOP39-K5J=T.I:E+)?W4)]4:5F$9]T"FO=JG%8Y3A[.FK(]#A?@:K@\9_
M:695.>KK:S;LWHVV[-NVFVGGI;\/O^"R7_*1?QQ_U[:9_P"D,-?;/_!$OP?I
MOQ"_X)Z>(M!UBUCOM)UCQ!J5E=V\@^6:*2"!64_4$U[5\<?^"9'P=_:+^)VH
M>,/%GAV]U#7M46)+B>/5;J!7$4:QI\B.%&%4#@<UZ%^SM^S7X0_96\ R>&?!
M.GS:;H\MY)?M#+=2W+&9PH8[I&9N0B\9QQ55L;"6'C2C>ZM^!&3\&XS#<05\
MSKN#I5'4TNV[2=U=-6VWU/PL_:O_ &<=0_96^/GB+P+J7F31Z;+OL;EQC[=9
M29,,OU*_*V.CHX[5^K__  2,_;';]IG]GM-#UJ[\[QEX%6.POC(W[R^ML$6]
MSZDE5*,?[Z$G[PKU/]I+]A?X9_M::UI>I>.- ?4M0T>%[:VN(;R:UD$3,&*,
M8V7<H89 .<$MC&369\ ?^"=OPK_9A^( \3>"]'U+2=6^S26CN=7N9HYHGP2C
MH[E6&54C(X*@BKQ&.I5Z"A-/F7W7_P""<G#_  3F>2YW/$X.<7AI-IQ;?-RO
M5:<K5XO9WU5]KGS/_P %?/\ @G3JOQ,U9OBMX#T^34=6C@6+Q!I5NNZ:\CC&
M$N8E_BD50%9!RRJI&2I!_/\ ^ _[1OC;]FCQ9+K'@G7KS0[Z3]U=1!1)#<A2
M?DFA<%6P<]1N7)P1S7]!%>-_'/\ X)__  C_ &BM3EU#Q-X-T^35IO\ 6:C9
M,]E=R'U>2(J7/N^:O!YHH0]C75XG/Q;X9U<7C7FF35?95F[M-M+F_F4HW<6^
MNCN]=-3\Q_&G_!7WXZ^./#DFF_\ "0Z5HJS)LDN=*TQ8+H@]<2,S;#[H 1V(
MKQ[X'_ SQ=^T[\28O#_A6PN=8U:\D\VZN)"S16BL<M/<2G.U<DDDY9CP 2<5
M^J.@_P#!&#X$Z+J*W$NBZ]J2*<^1=ZU.8C[$*5)'U-?1/PP^$'A?X*^&DT?P
MGH&E^']-0Y\BQMUB#G^\Q'+-_M,2?>NIYQAZ46L-#7TM_P .?-T?"O/<SQ$:
MG$.+YH1Z*4IRMU2YDE&_?7T.<_92_9PTG]E/X':/X-TI_M'V)3->W;+M:_NG
MYEF([9/ '954<XK\]_\ @JC_ ,$_]6^&/Q!U;XD^$]/FOO".N3->:K#;1EGT
M:Y8YD<J.?(D;+;APC,P. 5-?J=2.BR(RLH96&""."*\G"YA5H5G6WOOYGZAQ
M+P+E^;Y5'*FO9JFE[-K[#2LO56T:;U[IV:_##]G?]L'XA?LPR3_\(7X@>SL;
MQO-GL)XEN;.9N!O\MONL0 -R%2<#)-=1\=?^"A?Q7_:+\-2:'X@\00V^B7 Q
M<6.F6HM([H?W9""79?\ 9+;3W!K],/BA_P $T?@M\6-3FOK[P7::??7#;I)]
M*FDL#(>Y*Q,$)]RN:QO"'_!)GX'>$K];AO"]UJS(<JFI:E/<1@^Z;@I^A!%?
M0+.< Y>UE3?-Z+\[GXK+PHXSIT7EN'QT?J[TM[2HE9[KEY7OU2=F?G)^Q?\
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MCO-6\(Z3<:??:A;?9)GDOIK@-'N#XP[$#D#D<UZ^,XCHXC!.C)/G:\K7^_\
M0_-N&_ W,\EXKI9G0JPEA:<W)7E+VG*TTDURVNKVOS:VOI>Q^;O_  4L_P"3
MVO&W^]:?^DD-7OV9O^"B_BK]ESX9_P#"+Z/H/A_4;/[7+>>=>&;S=TF,CY6
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MU+6MTNN37EI(XZ+-$YRRD\'!Z=CTKZ]M[>.TMXXHD6..-0B(HPJ@<  >@I]
M'S-^P!^UOXJ^*^K^*OAK\4-/33?BA\/91%?2PQ%+;6;<G"W4? 7NN0O!#HP
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M9SRTLC=7D8\LQZGVP*ZJBBOGI2<G=[GXQ6K5*U256JW*4G=MZMM[ML*^??\
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M*/C9_P $]O@_^T5X]F\3^,O!\.M:Y<0QV\ERU]<Q%DC!"#;'(J\ GM7*V_\
MP2*_9XM+F.:/X=6JR0NLB'^T[WAE((/^N]10!Q7_  49_P"3TOV3_P#L:[O^
M5M7UAX^\":3\4/!.J^'==LH=0T?6K62SO+:4966-P01['G((Y! (Y%8OQ%^
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MY('-4?CO^PK\)?VEM3&H>,_ ^CZKJB@+]O0-;79 Z9EB*NV.VXG%<_\ "O\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45958402282432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 24, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 24,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6027 Edgewood Bend Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MV1O@^D8I\S:PF];J-X?)?U!+ P04    " " @3M:GZ ;\+$"  #B#   #0
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M?P%02P$"% ,4    " " @3M:!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ("!.UK7[AO][@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( ("!.UJ97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ @($[6DGJWC](!   ?Q   !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( ("!.UJ?H!OPL0(  .(,   -              "  8L,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ @($[6I>*NQS     $P(   L
M ( !9P\  %]R96QS+RYR96QS4$L! A0#%     @ @($[6JK$(A8S 0  (@(
M  \              ( !4!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M ("!.UHD'INBK0   /@!   :              "  ; 1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ("!.UIED'F2&0$  ,\#   3
M              "  942  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(  -\3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-20250124.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="nbix-20250124.htm">nbix-20250124.htm</File>
    <File>nbix-20250124.xsd</File>
    <File>nbix-20250124_lab.xml</File>
    <File>nbix-20250124_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20250124_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nbix-20250124.htm": {
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20250124",
   "dts": {
    "inline": {
     "local": [
      "nbix-20250124.htm"
     ]
    },
    "schema": {
     "local": [
      "nbix-20250124.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20250124_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20250124_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.neurocrine.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20250124.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20250124.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000914475-25-000006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-25-000006-xbrl.zip
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M'H8S-A1^>,>DW@AZ#W&''5D?V4CZ2*!40&T"V$AXN(6DY#3U$QZ(,%7^G"F
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M_8#GR5M1S2LL%]=:'5YW#Z@@N^)%HBC45'5BX7/<@5FY6K3 *I3*V8LN? B
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M[)%O/6_-#IZ[5 F9<I'%ZA?ED.X2KUA^^\7C^3C5AMJ*\J-)(M=\6 U& 5N
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M)&03C@DJ:(NI+F2,+4O4GG.4VN&UG;L7+E6_YYQLW#*<'O3^.GB6-FWEAXY
M12>"GH%F86/V576Y!IB@-Z?Z,K+5Y_T6N4[<!S(BO>8I6O;)%L_^\@X1TY!K
M.ZW<9,#T0B$9L/U2Z<*"#* %P-M!\!K%%<Q2QVO0MJ5<KSL*#['*_LQMC:C<
M!;+VP1LJ&W4-7P?<]M0L7L-!6XN>*&)> 5L,BX\6=X=\MD*4"1SQJV>4:O8
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MXQ&&\S,20QT9((["]9,!SX>&CSA.. +@W#"V+;B@)M=N'A-&J2RKD3:F7'"
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MHRHS62X6;>I<>6='8?;\@6GD\;KJP7!F2T""53H+[F;OWB)HPW"<#$##P\B
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M%!-9OQY_8V^%_P"TVT<GCCP7HVO74"[8[MXS#=1CL!-&5DP.PW8]JX;X?_\
M!*KX!_#?78=3L?AWIEY?6[!XI-3GFU!8R.F$F=D_,4 9G[ _Q\^)W[56O^+/
M'FO64/A_X6WTOD>#M,FL1'?740(S=229)*D#C P6=L$A03R'[*'_ "EF_:2_
M[!^C_P#HA:^Q884MX5CC58XXP%55&%4#H *Y#PI\ O"7@CXL>)/'&EZ2MKXH
M\71PQ:M>B>1C=K$H6,%&8HN  /E SWS0!\P>$]1M],_X+?>-I+FXAMX_^%=V
MP#2R!%)\Z#C)[U]?CQAI)/\ R%-.YX_X^4_QKRCXV?\ !/;X/_M%>/9O$_C+
MP?#K6N7$,=O)<M?7,19(P0@VQR*O )[5RMO_ ,$BOV>+2YCFC^'5JLD+K(A_
MM.]X92"#_KO44 <5_P %&?\ D]+]D_\ [&N[_E;5]8>/O FD_%#P3JOAW7;*
M'4-'UJUDL[RVE&5EC<$$>QYR".00".16+\1?@%X2^+'C3PGXA\0:2NH:QX'N
MGO=$N#/)']BF?;N8*K!6SL7A@1Q78T ?D3^T!=>)?@#XB^'?[/?BMKS4HO!/
MQ"TS6/".LRCY;_0Y)&1(V/\ ?BD;9Z#!7@*N?NW_ (*7_LQZU^T=\!;:Y\(D
M)X[\"ZE#XB\/G.&FGAY:$$\ NO3/&Y4S@9->F?&7]F+P+^T#J_AW4/%WAZVU
MB^\*78O=*N&EDBDM)0RMD-&RDKN1#M;*DJ.*[V@#P/\ 9$_X*"^"OVG?"D,-
MUJ%IX8\=6(^SZUX;U*06MY97*\2!$DPSIN!P1D@8# '(KL/C_P#M@?#K]F7P
M==:QXM\4:79K A:*SCG26]O&QPD4(.YF/3/ &>2!S5'X[_L*_"7]I;4QJ'C/
MP/H^JZHH"_;T#6UV0.F98BKMCMN)Q7/_  K_ ."8WP+^#GB"'5M'^'NDR:I;
MMNBN=0DEU!XCV*B9G4$=B!D4 5?^"??Q1^*WQY\'ZYXX^(EI:Z#H?B"\\SPI
MH@L_)NK2QRQ629S\S%P5"Y R$+8PXKS/_@FKK-GI/[2O[4WVJ[M;8R>/6*B6
M54W?-/TR:^T*^?\ QQ_P2X^!/Q(\9:KX@UKP';WVKZU=R7U[<-J-XIFFD8L[
M864*,DDX  H ]RMO%&FWDZQ0ZC8RR2'"HDZLS'V -?.NB_MY7'@_]N3Q-\)?
MB1:Z)X3TZ2VBO/!^K/*\2:U&V-R.[G8),DJ , M&XZ[0=[X;_P#!,?X'_"+Q
M[I/B?P[X%M].US1)_M-E=+J%W(8)-I7=M:4J>&/4'K7HGQQ_9O\  O[2GAR/
M2O'7AC2_$EG Q>$74?[RW8]3'(I#H3@9VL,X% '+?MJ?&/P#\.?V:/%TWC;4
MM(;2+[2;BW6SGE1GU%WC(2*).K,S$8P./O9 &1R/_!)GP1KWP_\ V!/ -AXB
MBN+>^D@GNXH)P5D@MYIY)8E(/(RC!L=@P%6/AW_P2M^ _P ,O%%OK-AX"L[O
M4+-Q);/J5W/?I;L.A6.9V3CMD'%?0M !1110 4444 %%%% !1110 4444 %%
M%% !1110!__94$L#!!0    ( ("!.UJ [#@'!PH  'U4   5    ;F)I>"TR
M,#(U,#$R-%]L86(N>&ULS9Q=;]LX%H;O^RNXV9M=8%CS2Y143#/H9MI%L9DV
M:%/,8!<+@U]*A+&E0%::Y-\O)=N)%$NV2,7JWB2.39_WO+0>D8<T\_,O]\L%
M^&Z*59IG;T_P:W0"3*9RG697;T^^77Z T<DOIZ]>_?P7"/_XQY=S\&NN;I<F
M*\%9841I-+A+RVM07AOP>U[\F7X7X&(ARB0OEA">UF\[RV\>BO3JN@0$D6#;
M;/MJ\2;$'!FD0TBYUI 936%$)8,$28%5)(0AYJ>K-]B^0"7A,$"1L<UB#D6
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M3^/</CI]M7TF7?^WRM-7_P-02P,$%     @ @($[6N2PP ND!@  XC   !4
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M_Y?*$_[?,?\&4$L! A0#%     @ @($[6LQM-YC(%0  7W0  !$
M     ( !     &YB:7@M,C R-3 Q,C0N:'1M4$L! A0#%     @ @($[6DS,
MDQA? @  _P8  !$              ( !]Q4  &YB:7@M,C R-3 Q,C0N>'-D
M4$L! A0#%     @ @($[6EAL^:,^1@  TD<  !0              ( !A1@
M &YB:7@M,C R-3 Q,C1?9S$N:G!G4$L! A0#%     @ @($[6H#L. <'"@
M?50  !4              ( !]5X  &YB:7@M,C R-3 Q,C1?;&%B+GAM;%!+
M 0(4 Q0    ( ("!.UKDL, +I 8  .(P   5              "  2]I  !N
M8FEX+3(P,C4P,3(T7W!R92YX;6Q02P$"% ,4    " " @3M:FJ'W ;4.   D
M,P  &@              @ $&<   ;F)I>#(P,C4Q,C<M97AH:6)I=#DY,2YH
8=&U02P4&      8 !@". 0  \WX

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>nbix-20250124_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20250124.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2025-01-24</startDate>
            <endDate>2025-01-24</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-01-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">6027 Edgewood Bend Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">617-7600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
